Serum Transthyretin Before and After Starting Tafamidis as Outcome Predictors in ATTR Cardiomyopathy

Key Points

• The aim is to assess the role of serum transthyretin levels before and after starting tafamidis in predicting treatment outcomes in ATTR cardiomyopathy.
• Participants with ATTR cardiomyopathy received tafamidis as treatment.
• Serum transthyretin levels were measured before and after treatment.
• Outcome markers were assessed to determine their predictive value.
• Higher baseline serum transthyretin levels correlated with better treatment outcomes (e.g., improvement in functional capacity).
• Post-treatment transthyretin levels were associated with significant changes in biomarkers with a p-value < 0.05.
• The analysis suggests monitoring transthyretin levels could improve patient management.